verapamil has been researched along with arsenic trioxide in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takeshita, A | 1 |
| Chen, H; Feng, T; Lu, Y; Shan, H; Yang, B; Zhang, Y; Zhao, X | 1 |
| Chen, X; Liu, LX; Zhang, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for verapamil and arsenic trioxide
| Article | Year |
|---|---|
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil | 2003 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for verapamil and arsenic trioxide
| Article | Year |
|---|---|
Arsenic trioxide-induced apoptosis in H9c2 cardiomyocytes: implications in cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line; Cell Survival; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Enzyme Activation; Myocytes, Cardiac; Oligopeptides; Oxidative Stress; Oxides; Rats; Reactive Oxygen Species; Verapamil; Vitamin E | 2008 |
The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxides; Phosphorylation; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Retinoblastoma Protein; Stomach Neoplasms; Time Factors; Tumor Suppressor Protein p53; Up-Regulation; Verapamil | 2009 |